Literature DB >> 21401699

Detection of CHK1 and CCND1 gene copy number changes in breast cancer with dual-colour fluorescence in-situ hybridization.

Kun Mu1, Li Li, Qingrui Yang, Tingguo Zhang, Peng Gao, Bin Meng, Zhiyan Liu, Yan Wang, Gengyin Zhou.   

Abstract

AIMS: To investigate the correlation between CCND1 amplification and CHK1 deletion in breast cancer, and to explore their role in tumorigenesis and progression, a comparative study of the gene copy number changes of CCND1 and CHK1 was performed with dual-colour fluorescence in-situ hybridization (FISH). METHODS AND
RESULTS: Sixty-one infiltrating ductal breast carcinomas with foci of ductal carcinoma in situ (DCIS) components were selected for dual-colour FISH. A strong correlation was found between CCND1 amplification and CHK1 deletion (P<0.0001). Fourteen cases were detected that demonstrated both CCND1 amplification and CHK1 deletion. Interestingly, when comparing the infiltrating and non-invasive areas for the same tumour, we found three cases with CCND1 amplification in the infiltrating areas but not in the DCIS areas. We did not find a CHK1 gene profile difference between infiltrating and DCIS areas in the same lesions.
CONCLUSIONS: Our findings suggest that CCND1 amplification and CHK1 deletion are common events in breast cancer, and that the two genetic alterations often coexist. Our data also suggest that CHK1 deletion is an early genetic event in the development of breast cancer and can be detected at the DCIS stage, whereas CCND1 amplification is more likely to be associated with tumour progression.
© 2011 Blackwell Publishing Limited.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21401699     DOI: 10.1111/j.1365-2559.2011.03780.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  6 in total

Review 1.  Cell cycle proteins as promising targets in cancer therapy.

Authors:  Tobias Otto; Piotr Sicinski
Journal:  Nat Rev Cancer       Date:  2017-01-27       Impact factor: 60.716

2.  Inference of tumor phylogenies from genomic assays on heterogeneous samples.

Authors:  Ayshwarya Subramanian; Stanley Shackney; Russell Schwartz
Journal:  J Biomed Biotechnol       Date:  2012-05-13

Review 3.  Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast.

Authors:  Jia-Min B Pang; Kylie L Gorringe; Stephen Q Wong; Alexander Dobrovic; Ian G Campbell; Stephen B Fox
Journal:  Breast Cancer Res       Date:  2015-06-16       Impact factor: 6.466

Review 4.  Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy.

Authors:  Gwenola Manic; Florine Obrist; Antonella Sistigu; Ilio Vitale
Journal:  Mol Cell Oncol       Date:  2015-02-23

5.  Over expression of hRad9 protein correlates with reduced chemosensitivity in breast cancer with administration of neoadjuvant chemotherapy.

Authors:  Haiqin Yun; Ranran Shi; Qingrui Yang; Xiaofang Zhang; Yan Wang; Xingchen Zhou; Kun Mu
Journal:  Sci Rep       Date:  2014-12-18       Impact factor: 4.379

6.  Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma.

Authors:  Angela B Ortiz; Diego Garcia; Yolanda Vicente; Magda Palka; Carmen Bellas; Paloma Martin
Journal:  PLoS One       Date:  2017-11-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.